Risk of Cardiovascular Disorders in Psoriasis Patients
- 494 Downloads
Psoriasis is an inflammatory autoimmune disease that affects the skin. Recently, psoriasis and its consequential lifestyle and dietary habits have been associated with increased risks for cardiovascular diseases. This article discusses the connection between cardiovascular disorders and psoriasis and the effects of available treatment options on cardiovascular risk. A PubMed search revealed 11 articles that were analyzed for information regarding this association, its effects, and potential courses of treatment. Both the presence and severity of psoriasis increases the risk for cardiovascular disorders and co-morbidities. Forty percent of psoriasis patients met metabolic syndrome criteria as compared with 23 % of non-psoriasis control subjects. Rate ratios for atrial fibrillation are correlated with the severity of psoriasis; patients with severe and mild psoriasis produced rate ratios of 1.63 and 1.31, respectively. Studies also show an increase in the risks for myocardial infarction, atherosclerosis, ischemic stroke, and other cardiovascular disorders. The exact mechanisms behind this affiliation are still uncertain; however, the psychological and physiological effects of psoriasis and the overlapping pathogenesis behind atherosclerosis and psoriasis may play a role. Since the risk for cardiovascular disorders increases with the presence and severity of psoriasis, psoriasis treatment should not only address the disease and its symptoms, but also its co-morbidities. Recent National Psoriasis Foundation (NPF) guidelines have provided recommendations for psoriasis patient care. Histories of co-morbidities, screenings for potential diseases, increased exercise, decreased alcohol consumption, and smoking cessation should be implemented. Unfortunately, while there are data for the increased risk for cardiovascular diseases within psoriasis patients, there are presently no data stating that increasing cardiovascular screening rates in patients produces a significant difference.
KeywordsAtrial Fibrillation Psoriasis Ischemic Stroke Cardiovascular Disorder Psoriasis Patient
The Center for Dermatology Research is supported by an unrestricted educational grant from Galderma Laboratories, L.P. Dr. Feldman is a consultant and speaker for Galderma, Stiefel/GlaxoSmithKline, Abbott Labs, Warner Chilcott, Janssen, Amgen, Photomedex, Genentech, BiogenIdec, and Bristol Myers Squibb. Dr. Feldman has received grants from Galderma, Astellas, Abbott Labs, Warner Chilcott, Janssen, Amgen, Photomedex, Genentech, BiogenIdec, Coria/Valeant, Pharmaderm, Ortho Pharmaceuticals, Aventis Pharmaceuticals, Roche Dermatology, 3M, Bristol Myers Squibb, Stiefel/GlaxoSmithKline, Novartis, Medicis, Leo, HanAll Pharmaceuticals, Celgene, Basilea, and Anacor and has received stock options from Photomedex. Ms. Tablazon, Mr. Al-Dabagh, and Mr. Davis have no conflicts of interest to disclose.
- 1.Fernandez-Torres R, Pita-Fernandez S, Fonseca E. Psoriasis and cardiovascular risk: assessment by different cardiovascular risk scores. J Eur Acad Dermatol Venereol. 2012. [Epub ahead of print].Google Scholar
- 8.Jensen P, Thyssen JP, Zachariae C, et al. Cardiovascular risk factors in subjects with psoriasis: a cross-sectional general population study. Int J Dermatol. 2012. [Epub ahead of print].Google Scholar
- 24.McDonald I, Connolly M, Tobin AM. A review of psoriasis, a known risk factor for cardiovascular disease and its impact on folate and homocysteine metabolism. J Nutr Metab. 2012. [Epub ahead of print].Google Scholar
- 40.Gudjonsson JE, Elder JT. Psoriasis. In: Goldsmith LA, Katz SI, Wolff K, et al., editors. Fitzpatrick’s dermatology in general medicine. New York: McGraw Hill; 2008. p. 169–74.Google Scholar
- 44.Kimball AB, Gordon KB, Langley RG, et al. Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial. Arch Dermatol. 2008;144(2):200–7.PubMedCrossRefGoogle Scholar
- 49.Tzellos T, Kyrgidis A, Zouboulis CC. Re-evaluation of the risk for major adverse cardiovascular events in patients treated with anti-IL-12/23 biological agents for chronic plaque psoriasis: a meta-analysis of randomized controlled trials. J Eur Acad Dermatol Venereol. 2012. [Epub ahead of print].Google Scholar
- 57.Martin SL, McGoey ST, Bebo Jr BF, et al. Patients’ educational needs about topical treatments for psoriasis. J Am Acad Dermatol. 2012. [Epub ahead of print].Google Scholar